HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance: Which Salvage Regimen?

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.31, Iss.5, 2011-05, pp. : 345-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidemiology of end-stage renal disease

By Roderick Paul

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Anorexia in end-stage renal disease: pathophysiology and treatment

By Alvarez Vicente Diéz Juan Jose Aguilera Abelardo Selgas Rafael Codoceo Rosa Bajo Maria A

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 11, 2001-11 ,pp. : 1825-1838

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K Zussman B Miller AK Freed MI

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Approach to the management of end-stage renal disease

By Rodger R Stuart C

Clinical Medicine, Vol. 12, Iss. 5, 2012-10 ,pp. : 472-475

Royal College Of Physicians

Access to resources Recommend Favorite

End-stage renal disease onset a costly event

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite